Knowledge, action and resistance: the selective use of pre-natal screening among Bedouin women of the Negev, Israel

The selective use of prenatal screening by Bedouin women attending Ministry of Health, maternal and child health clinics in Israel is examined. The data consist of a review of 537 prenatal care records, 16 in depth interviews with mothers, and four interviews with health personnel. These data are part of a larger study that took place between 1994-99 amongst Negev Bedouin women, part of the Palestinian Arab minority within Israel. The record review shows that the majority of women who attend prenatal care do not take up referrals for Maternal Serum Alpha Feto Protein (MSAFP) testing or for amniocentesis tests. Although many women interviewed talked about the value of prenatal screening, they also spoke of 'false alarms' that may result from testing. Similarly, women were aware that the socially preferred pattern of consanguinity in marriage amongst the Bedouin may cause medical problems, however test uptake was unrelated to consanguinity. There was a variety of views concerning the permissibility of terminating a pregnancy. This study shows that women use prenatal screening selectively in a way that helps them to balance social and medical risk.     

Osteotome sinus floor elevation using Choukroun's platelet-rich fibrin as grafting material: a 1-year prospective pilot study with microthreaded implants.

OBJECTIVES: The aim of this prospective study was to document, radiographically, changes in the apical bone levels on microthreaded implants placed in subsinus residual bone height, according to a bone-added osteotome sinus floor elevation technique with platelet-rich fibrin (PRF) as grafting material. STUDY DESIGN: Implants were placed using PRF as grafting material in the bone-added osteotome sinus floor elevation (BAOSFE) technique. The survival rate at abutment tightening (6 to 12 weeks of healing) and at 1 year was calculated. The radiographic analysis determined on consecutive radiographs: 1) the mean residual bone height (RBH) under the maxillary sinus at implant placement; and 2) the change in endosinus bone level. Mean and standard deviation were used to assess the endosinus bone changes in the mesial and distal implant sides at 1 year. RESULTS: Between December 2004 and June 2005, 20 consecutive patients were included in the study after bone height measurement by periapical radiographs. Patients included 14 women (70%) and 6 men (30%) with a mean age of 54.8 +/- 11.1 years, range 35 to 73 years; they were treated with 35 Astra Tech implants (Astra Tech Dental Implant System; Astra Tech, M?lndal, Sweden) fulfilling the inclusion criteria. The mean healing time before abutment tightening was 8.3 +/- 1.4 weeks (range 6-12 weeks); by this time, 1 implant was mobile and was removed. At 1 year, all implants were clinically stable and the definitive prostheses were in function, resulting in a survival rate of 97.1%. Nineteen implants (55%) were 11 mm long, 6 implants (17%) were 9 mm, 5 implants (14%) were 8 mm, and 5 implants (14%) were 13 mm. The RBH was measured after implant placement on the radiographs on both implant sides. The mean RBH was 6.5 +/- 1.7 mm: 6.3 +/- 1.3 on the mesial side and 6.7 +/- 2.0 mm on the distal side. Measurements of the changes in the endosinus level on the mesial and distal sides showed that all implants gained endosinus bone. The mean endosinus gain was 3.2 +/- 1.5 mm: 3.5 +/- 1.4 mm on the mesial side and 2.9 +/- 1.6 mm on the distal side. The lowest bone gain was 0.9 mm and 0.1 mm on the mesial and distal sides, respectively. The highest gain was 5.8 mm and 5.2 mm on the mesial and distal sides, respectively. CONCLUSIONS: The BAOSFE procedure with PRF as grafting material can lead to an endosinus bone gain. Despite a limited RBH, a healing period of 2-3 months was found to be sufficient to resist a torque of 25 N.cm applied during abutment tightening. At 1 year, formation of a new recognizable bone structure delimiting the sinus floor was identified radiologically and led to a predictable implant function.     

A novel function for programmed death ligand-1 regulation of angiogenesis

Programmed death ligand-1 (PD-L1) plays a critical role in T-cell regulatory function. Here, we report a newly discovered effect of PD-L1 on angiogenesis. We demonstrate that PD-L1 and its receptor CD80, but not PD-1, are expressed by primary murine lung and heart vascular endothelial cells and the miscrovascular endothelial cell line (MS1) at both the mRNA and protein levels in vitro. The inhibition of PD-L1 or CD80 expression in MS1 cells, by small-interfering RNA transfection, led to a significant up-regulation of vascular endothelial growth factor receptor 2 expression and cell proliferation levels in MS1 cells. Furthermore, MS1 cells were found to have a significantly lower proliferation and vascular endothelial growth factor receptor 2 expression levels when they were co-cultured with PD-L1-expressing normal corneal epithelial cells, as compared to MS1 cells co-cultured with PD-L1(-/-) corneal epithelial cells. In a suture-induced corneal angiogenesis model, we observed a significantly higher level of angiogenic response in PD-L1(-/-) knockout mice as compared to wild-type mice, although there was no significant difference in the expression of inflammatory cytokines (interleukin-1α, interleukin-1β, or tumor necrosis factor-α) or the infiltration of innate immune cells (neutrophils and macrophages) between the two groups. We conclude that the expression of PD-L1 in both vascular endothelial cells and corneal epithelial cells regulates corneal angiogenesis.     

Molecular genetic analysis of BAX and cyclin D1 genes in patients with malignant glioma

INTRODUCTION AND OBJECTIVES: Brain tumorigenesis is a complex process involving multiple genetic alterations. Cyclin D1 and BAX genes are two of the most important regulators in controlling the normal proliferation and apoptosis of cells, respectively. In this study, we analysed the possibilities of involvement of cyclin D1 and BAX genes in the gliomagenesis. METHODS AND RESULTS: In determining gene alterations of exon 4 of cyclin D1 gene and exon 6 of BAX gene, all samples were amplified by polymerase chain reaction (PCR) and subsequently by direct sequencing. Our results showed a frameshift mutation (G base deletion) at nucleotide 82 of codon 28 in exon 4 of the cyclin D1 gene and another frameshift mutation with a deletion of C base at nucleotide 153 of exon 6 of the BAX gene in two separate cases of a glioblastoma multiform (WHO Grade IV) sample. CONCLUSION: These findings suggest that both cyclin D1 and BAX genes alteration are rarely found in brain tumors. However, the alteration might cause a significant effect of the normal protein production and this might contribute to the development of brain tumorigenesis in Malaysian patients.